1. Home
  2. NTZ vs SCYX Comparison

NTZ vs SCYX Comparison

Compare NTZ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTZ
  • SCYX
  • Stock Information
  • Founded
  • NTZ 1959
  • SCYX 1999
  • Country
  • NTZ Italy
  • SCYX United States
  • Employees
  • NTZ N/A
  • SCYX N/A
  • Industry
  • NTZ Home Furnishings
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NTZ Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • NTZ Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • NTZ 51.8M
  • SCYX 50.3M
  • IPO Year
  • NTZ 1993
  • SCYX 2014
  • Fundamental
  • Price
  • NTZ $4.91
  • SCYX $1.12
  • Analyst Decision
  • NTZ
  • SCYX Buy
  • Analyst Count
  • NTZ 0
  • SCYX 1
  • Target Price
  • NTZ N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • NTZ 15.4K
  • SCYX 316.4K
  • Earning Date
  • NTZ 12-12-2024
  • SCYX 11-06-2024
  • Dividend Yield
  • NTZ N/A
  • SCYX N/A
  • EPS Growth
  • NTZ N/A
  • SCYX N/A
  • EPS
  • NTZ N/A
  • SCYX N/A
  • Revenue
  • NTZ $365,846,531.00
  • SCYX $8,566,000.00
  • Revenue This Year
  • NTZ N/A
  • SCYX N/A
  • Revenue Next Year
  • NTZ N/A
  • SCYX $365.06
  • P/E Ratio
  • NTZ N/A
  • SCYX N/A
  • Revenue Growth
  • NTZ N/A
  • SCYX N/A
  • 52 Week Low
  • NTZ $3.80
  • SCYX $0.90
  • 52 Week High
  • NTZ $6.50
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • NTZ 56.77
  • SCYX 44.06
  • Support Level
  • NTZ $4.63
  • SCYX $1.12
  • Resistance Level
  • NTZ $4.93
  • SCYX $1.49
  • Average True Range (ATR)
  • NTZ 0.33
  • SCYX 0.10
  • MACD
  • NTZ 0.02
  • SCYX -0.00
  • Stochastic Oscillator
  • NTZ 92.18
  • SCYX 27.31

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio including sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of revenue from the United States of America and also has an international presence in Italy, Spain, UK and Other countries.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: